Stockscreener 앱 받기
70.07
0.07%
-0.05
시간 외 거래:
70.13
0.06
+0.09%
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio (BBIO) CEO Neil Kumar awarded options and 104,313 RSUs - Stock Titan
BridgeBio Pharma launches initiative to define age-specific pathways for FGFR3 testing - Traders Union
Mizuho raises BridgeBio Pharma stock price target on drug strength By Investing.com - Investing.com Canada
Mizuho Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BBIO: Mizuho Raises Price Target to $106, Maintains 'Outperform' Rating | BBIO Stock News - GuruFocus
Raymond James Maintains BridgeBio Pharma (BBIO) Outperform Recommendation - MSN
Aug Sectors: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARMarket Performance Summary & Entry Point Strategy Guides - baoquankhu1.vn
Resistance Check: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEAR2026 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
BBIO PE Ratio & Valuation, Is BBIO Overvalued - Intellectia AI
(BBIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Fred Alger Management LLC Has $10.25 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma CEO Kumar Neil sells $5.5m in BBIO stock - Investing.com Nigeria
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio (BBIO) CEO’s family trusts sell 80,000 company shares - Stock Titan
HighVista Strategies LLC Raises Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Granahan Investment Management LLC Buys 78,588 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Farallon Capital Management LLC Has $425.49 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback - Yahoo Finance
The week in pharma: action, reaction and insight – week to March 13, 2026 - The Pharma Letter
Boone Capital Management LLC Buys Shares of 460,282 BridgeBio Pharma, Inc. $BBIO - MarketBeat
Prosight Management LP Sells 208,187 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BBIO6336503 Bond Risk Analysis - TradingView
BBIO6336503 Bond Coupon Analysis — Rate & Payments - TradingView
How Positive Phase 3 LGMD Data Could Shape BridgeBio Pharma’s (BBIO) Risk Profile and Upside Potential - simplywall.st
BBIO (NASDAQ: BBIO) — Trustee and Insider 10b5-1 Sales Listed - Stock Titan
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Tenet Healthcare (THC) - The Globe and Mail
BridgeBio Touts Attruby Uptake, Bayer's Europe Rollout, and Pipeline Timelines - National Today
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf - MarketBeat
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - MarketBeat
BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9 - Citeline News & Insights
BridgeBio Pharma Director Sells Shares - TradingView
BridgeBio director sells 8,671 shares after option exercise | BBIO SEC FilingForm 4 - Stock Titan
BridgeBio (BBIO) soars 13% on double-digit price target upgrade - MSN
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - simplywall.st
BridgeBio reports Phase III progress for BBP-418 - The Pharma Letter
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Barclays Maintains Overweight on BridgeBio Pharma (BBIO) March 2026 - Meyka
Capital Research Global Investors Sells 2,055,172 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026 - Meyka
BridgeBio (BBIO) Reports Promising Phase 3 Data for BBP-418 in M - GuruFocus
BridgeBio Pharma Presents Promising Phase 3 FORTIFY Interim Analysis Results for BBP-418 in LGMD2I/R9 at MDA Conference - Quiver Quantitative
BridgeBio Pharma plans to submit NDA for BBP-418 to FDA in H1 2026 - marketscreener.com
Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026 - TradingView
LGMD trial drug lets people finish 100m test 31s faster than placebo - Stock Titan
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13% - AlphaStreet
HC Wainwright Raises Earnings Estimates for BridgeBio Pharma - MarketBeat
BridgeBio (BBIO) Sees Price Target Boost and Earns Overweight Ra - GuruFocus
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
U.S. Indexes Finished Mixed Tuesday As BridgeBio Pharma Led, Centene Lagged - Barron's
Valantine plans option-based sale; prior 25,484 shares sold (BBIO) - Stock Titan
Barclays reiterates Overweight on BridgeBio Pharma stock By Investing.com - Investing.com Canada
BridgeBio’s Price Target Boost Sparks Investor Excitement - StocksToTrade
Why Is BridgeBio Pharma Stock Soaring Tuesday?BridgeBio Pharma (NASDAQ:BBIO) - Benzinga
JP Morgan Raises Price Target for BridgeBio Pharma (BBIO) to $94 - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 9.3%Should You Buy? - MarketBeat
BridgeBio Pharma shares jump as investors focus on fresh BBP-418 data at MDA meeting and near-term regulatory milestones - Quiver Quantitative
BridgeBio Pharma’s Surge: A Closer Look at Market Dynamics - StocksToTrade
BridgeBio Pharma’s Growth Momentum Backed by Analyst Confidence - timothysykes.com
BridgeBio Pharma Jumps as Wall Street Piles In - TipRanks
William Blair initiates BridgeBio stock with outperform rating - Investing.com India
William Blair initiates BridgeBio stock with outperform rating By Investing.com - Investing.com South Africa
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at William Blair - MarketBeat
William Blair Initiates BridgeBio Pharma at Outperform - marketscreener.com
FY2027 Earnings Estimate for BBIO Issued By HC Wainwright - MarketBeat
Victory Capital Management Inc. Purchases 141,800 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):